share_log

Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate

Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate

Atea Pharmaceuticals 2024 年第一季度每股收益为 0.75 美元 (0.75) 未达到预期 (0.61)
Benzinga ·  05/15 04:16

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 74.42 percent decrease over losses of $(0.43) per share from the same period last year.

Atea Pharmicals(纳斯达克股票代码:AVIR)公布的季度亏损为每股0.75美元,比分析师普遍预期的0.61美元(0.61美元)低22.95%。与去年同期每股亏损0.43美元(0.43)相比,下降了74.42%。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发